Invesco
NGNE icon

Invesco’s Neurogene NGNE Stock Holding History

Invesco’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121,837
Closed -$5.11M – 3794
2024
Q3 		$5.11M Sell
121,837
-11,857
-9% -$460K ﹤0.01% 2209
2024
Q2 		$4.87M Buy
133,694
+11,330
+9% +$400K ﹤0.01% 2198
2024
Q1 		$6.23M Buy
+122,364
New +$4.09M ﹤0.01% 2088
2022
Q2 		– Sell
-562
Closed -$21K – 4107
2022
Q1 		$21K Buy
562
+4
+0.7% +$233 ﹤0.01% 3988
2021
Q4 		$53K Sell
558
-234
-30% -$28.5K ﹤0.01% 3975
2021
Q3 		$115K Buy
792
+88
+13% +$13.5K ﹤0.01% 3913
2021
Q2 		$130K Buy
+704
New +$156K ﹤0.01% 3858
2020
Q3 		– Sell
-1,200
Closed -$399K – 3675
2020
Q2 		$399K Buy
1,200
+107
+10% +$27.9K ﹤0.01% 3238
2020
Q1 		$249K Buy
+1,093
New +$225K ﹤0.01% 3331

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco's NGNE Position: Q4 2024 in Review

Invesco sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 121,837 shares — an estimated $5.11M sold.

Invesco first reported a position in NGNE in Q1 2020 and held it in 9 quarters. The position peaked at $6.23M in Q1 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • Invesco reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • Invesco sold 121,837 Neurogene shares in Q4 2024, an estimated $5.11M.
  • Invesco first reported a position in Neurogene in Q1 2020 and held it in 9 quarters.
  • Invesco's Neurogene position peaked at $6.23M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Invesco's 13F filing for Q4 2024, filed 13 Feb 2025.